Clinical Trial Update: Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously [Phase 4]

View source ↗

Summary

A Phase 4 open, randomized two-way crossover trial in gastroesophageal reflux disease evaluating 40 mg doses given orally and intravenously; sponsor AstraZeneca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Snippet

Sponsor: AstraZeneca | Conditions: GERD | Phase 4 | Status: COMPLETED